Bioventix PLC (LON:BVXP) had its price target hoisted by FinnCap from GBX 1,350 ($16.71) to GBX 1,450 ($17.95) in a research report issued on Monday. The brokerage presently has a “corporate” rating on the biotechnology company’s stock. FinnCap’s price target would indicate a potential downside of 7.64% from the company’s current price.

Shares of Bioventix PLC (LON:BVXP) opened at 1570.00 on Monday. The firm’s market cap is GBX 79.30 million. The company has a 50 day moving average of GBX 1,158.61 and a 200 day moving average of GBX 1,044.63. Bioventix PLC has a 52 week low of GBX 899.50 and a 52 week high of GBX 1,600.00.

Bioventix PLC Company Profile

Bioventix PLC, based in the United Kingdom, is engaged in the development and supply of antibodies. The Company is a biotechnology company specializing in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing.

Receive News & Ratings for Bioventix PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventix PLC and related companies with's FREE daily email newsletter.